INTRODUCTION: Although most of the controlled drug delivery systems are designed for subcutaneous, transdermal, or intramuscular uses, others can also deliver drugs in to blood stream. This type of approach to drug delivery has become quite appealing for a number of classes of drugs, particularly those that cannot be given via oral route 1 .Also many new biotechnology-based drug and compounds are not suitable to be administered via the oral route. Thus parenteral drug delivery has received significant research interest in last two decades 2. Parenteral administration of drug molecule is advantageous for easy access to systemic circulation with rapid drug absorption. This rapid drug absorption is unfortunately also accompanied by a rapid decline in the drug levels in the systemic circulation. In chronic conditions, parenteral formulations results in to quick decline of drug levels in systemic circulation which is not advantageous and needs to take multiple injections for years or even lifetime. For the effective treatment it is often desirable to maintain systemic drug levels within the therapeutically effective concentration range for as long as treatment calls for. For this purpose new injectable drug delivery system has been developed which is called as parenteral depot formulation or insitu forming parenteral system, also known as in-situ forming implant (ISFI) 3. Figure 1: In-situ gel forming implantable system.

The present investigation deals with the formulation, optimization and evaluation of liquid crystalline cream of Tolnaftate. Brij-78 used as a surfactant, Cetostearyl alcohol was used as a co-surfactant and Silicon oil as a oil phase. Liquid crystalline cream system, has a potential for efficient delivery of Tolnaftate (1%), as topical dermal drug delivery system. The liquid crystalline system enhance the diffusion of water insoluble drug Tolnaftate through the skin for effective result. Liquid crystals (LC) are substances that flow like liquids but maintain some of the ordered structure characteristics of crystalline solids. Based on the ways that LCs are generated, they can be classified into two types 1) Thermotropic LCS and 2) Lyotropic LCs. Incorporation of the drug in liquid crystal increased its antimycotic activity against different antifungal microorganisms. Used surfactant enhance the penetration of drug and also improve the solubility of drug. The objective of this study was to increase the diffusion coefficient of drug through the formulation, and also to improve the availability of drug at the site of action. The prepared liquid crystalline cream exhibited the expected, viscosity, drug content, pH, spreadability, in vitro drug release and in vitro antimycotic inhibitory activity. Liquid crystalline cream for tolnaftate was found to be stable cream. It was found to have better in vitrorelease profile characteristics, and in vitro antimycotic activity, it can be concluded that the formulation F5 has better potential of antimicrobial activity and to enhance the diffusion of drug through the cream.

The overall objective of this research project was to study the in DPI formulations containing ICH and LABA to achieve efficient drug deposition goals. Hence, this project focused on the formulation development of DPIs and impact of different fill weight or fill volume in performance as well as other physicochemical parameter. The performance mainly APSD of dry powder inhalers containing LABA & ICS was found to be optimum when it is formulated with 30% of fine grade lactose monohydrate. The APSD evaluation was concluded that the deposition of particle of (F8) 12.5 mg is better than (F4) 25 mg. It's may due to more void space in the 12.5 mg capsule formulation than 25 mg capsule formulation. Due to this good turbulence occurs and separation drug particle form carrier surface is more and give better deposition compared to 25 mg fill weight formulation per capsule. The overall project concluded the 12.5mg formulation (F8) is good. These formulations are advantages over 25 mg formulation such as less carrier residue, cost effective, good therapeutic result.